Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT07658846

Hippo-Related Competing Endogenous RNA (ceRNA) Network Dysregulation and In Vitro Fertilization (IVF) Outcomes in Women With Diminished Ovarian Reserve

Conditions: Diminished Ovarian Reserve, Female Infertility, In Vitro Fertilization

Sex: Female
Ages: 18 Years – 40 Years
Healthy volunteers: No
Enrollment: 70
Sponsor: Assiut University

Location: Faculty of Medicine, Assiut University Asyut

Summary

Diminished Ovarian Reserve (DOR) is an important cause of female infertility and is associated with poor ovarian response and lower pregnancy rates during In Vitro Fertilization (IVF). The molecular mechanisms underlying impaired follicular development in DOR remain incompletely understood. Increasing evidence suggests that non-coding RNAs and components of the Hippo signaling pathway play important roles in granulosa cell proliferation, apoptosis, and follicular development. This prospective observational cohort study aims to investigate the expression of the long non-coding RNA (lncRNA) Nuclear Paraspeckle Assembly Transcript 1 (NEAT1), microRNA (miRNA)-181a-5p, Hippo pathway components including Yes-Associated Protein 1 (YAP1) and Connective Tissue Growth Factor (CTGF), and Insulin-Like Growth Factor 1 (IGF1) in follicular fluid-derived cells from women with DOR undergoing IVF compared with women with normal ovarian reserve. The study will also evaluate relationships among these molecular markers and IVF outcomes, including oocyte quality, number of retrieved oocytes, and embryo developmental potential.

Eligibility Criteria

Inclusion Criteria: * Women undergoing In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) cycles. * Infertility duration of at least one year * Primary or secondary infertility. Exclusion Criteria: * Polycystic Ovary Syndrome (PCOS) * Endometriosis. * Ovarian tumors or malignancy. * Severe systemic diseases affecting fertility. * Metabolic syndrome. * Connective tissue disorders. * Hormonal therapy within the last three months. * Refusal to participate.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07658846). StuddyBuddy aggregates publicly available trial information.